The Bakersfield Californian2d
Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues
Humacyte, Inc. (NASDAQ: HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District ...
TMCnet5d
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humacyte, Inc. (HUMA)
for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication." The press release disclosed in part, that, "[d]uring the course of the BLA review, the FDA has conducted ...
Humacyte sees success in dual emergency-engineered tissue trials
The two studies of the company’s engineered vascular tissue saw success with casualties in Ukraine and the US.
Humacyte announces publication of results on ATEV
Humacyte (HUMA) announced the publication of clinical results evaluating the efficacy and safety of the acellular tissue engineered vessel, ...
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance ...